PRA Advances to Become PRA Health Sciences

RALEIGH, N.C., June 16, 2014 -- PRA, a leading clinical research organization, today announced that it has changed its name to PRA Health Sciences (PRA). The name change to PRA Health Sciences is the culmination of several strategic actions which support and enhance the company's commitment to the future of clinical development. 

Starting over 18 months ago, PRA strategically strengthened its coverage of China and created a joint venture with the leading clinical development firm in China, forming WuXiPRA. PRA then bolstered its capabilities in Russia and Eastern Europe by acquiring ClinStar, the premier provider of CRO services in Russia and Eastern Europe. With the subsequent acquisition of RPS, the pioneer of the Embedded Solutions™ model, PRA enhanced its ability to offer a more comprehensive breadth of services across all segments of the biopharmaceutical industry.  At the close of 2013, PRA purchased CRI Lifetree, which augmented its existing Phase I and bioanalytical capabilities, cementing PRA as the most comprehensive, high-end Phase I organization in the world.

"The expansion of our global presence, the growth in our breadth of services, and the deepening of our capabilities we initiated over the last year-and-a-half enable us to better serve our clients," said Colin Shannon, president and CEO, PRA Health Sciences. "This change to our name reflects our historical roots as a scientifically rich company, the breadth and depth of our solutions, and most importantly, our dedication to working with sponsors to bring new treatments to market that will positively impact the lives of patients and their families." 

As one unified company with a broad range of specific expertise, PRA is well-equipped and intently focused on working to improve the lives of patients and providing innovative solutions that will drive the future of clinical development.

In addition to the new name, PRA is introducing a new website more reflective of the company today. This new interactive, website can be experienced at:

At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs.  PRA has more than 10,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace.  As a top five CRO, we have worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 45+ such drugs.

To learn more about PRA, please visit:

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.